522 related articles for article (PubMed ID: 19038308)
41. Synergistic control of sex hormones by 17β-HSD type 7: a novel target for estrogen-dependent breast cancer.
Wang X; Gérard C; Thériault JF; Poirier D; Doillon CJ; Lin SX
J Mol Cell Biol; 2015 Dec; 7(6):568-79. PubMed ID: 25966904
[TBL] [Abstract][Full Text] [Related]
42. Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells.
Gonzalez A; Cos S; Martinez-Campa C; Alonso-Gonzalez C; Sanchez-Mateos S; Mediavilla MD; Sanchez-Barcelo EJ
J Pineal Res; 2008 Aug; 45(1):86-92. PubMed ID: 18298468
[TBL] [Abstract][Full Text] [Related]
43. Estrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.
Hilborn E; Stål O; Jansson A
Oncotarget; 2017 May; 8(18):30552-30562. PubMed ID: 28430630
[TBL] [Abstract][Full Text] [Related]
44. High expression of steroid sulfatase mRNA predicts poor prognosis in patients with estrogen receptor-positive breast cancer.
Miyoshi Y; Ando A; Hasegawa S; Ishitobi M; Taguchi T; Tamaki Y; Noguchi S
Clin Cancer Res; 2003 Jun; 9(6):2288-93. PubMed ID: 12796397
[TBL] [Abstract][Full Text] [Related]
45. Biochemical and biological evaluation of novel potent coumarin inhibitor of 17β-HSD type 1.
Starčević S; Kocbek P; Hribar G; Rižner TL; Gobec S
Chem Biol Interact; 2011 May; 191(1-3):60-5. PubMed ID: 21232530
[TBL] [Abstract][Full Text] [Related]
46. Estradiol-independent modulation of breast cancer transcript profile by 17beta-hydroxysteroid dehydrogenase type 1.
Aka JA; Calvo EL; Lin SX
Mol Cell Endocrinol; 2017 Jan; 439():175-186. PubMed ID: 27544780
[TBL] [Abstract][Full Text] [Related]
47. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells.
Miki Y; Suzuki T; Tazawa C; Yamaguchi Y; Kitada K; Honma S; Moriya T; Hirakawa H; Evans DB; Hayashi S; Ohuchi N; Sasano H
Cancer Res; 2007 Apr; 67(8):3945-54. PubMed ID: 17440110
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases.
Frotscher M; Ziegler E; Marchais-Oberwinkler S; Kruchten P; Neugebauer A; Fetzer L; Scherer C; Müller-Vieira U; Messinger J; Thole H; Hartmann RW
J Med Chem; 2008 Apr; 51(7):2158-69. PubMed ID: 18324762
[TBL] [Abstract][Full Text] [Related]
49. Expression of estrogen and progesterone receptors and estrogen metabolizing enzymes in different breast cancer cell lines.
Hevir N; Trošt N; Debeljak N; Rižner TL
Chem Biol Interact; 2011 May; 191(1-3):206-16. PubMed ID: 21182832
[TBL] [Abstract][Full Text] [Related]
50. Enzymes as modulators in malignant transformation.
Vihko P; Herrala A; Härkönen P; Isomaa V; Kaija H; Kurkela R; Li Y; Patrikainen L; Pulkka A; Soronen P; Törn S
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):277-83. PubMed ID: 15860271
[TBL] [Abstract][Full Text] [Related]
51. 17Beta-hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines.
Day JM; Tutill HJ; Newman SP; Purohit A; Lawrence HR; Vicker N; Potter BV; Reed MJ
Mol Cell Endocrinol; 2006 Mar; 248(1-2):246-9. PubMed ID: 16490301
[TBL] [Abstract][Full Text] [Related]
52. Differential androgen and estrogen substrates specificity in the mouse and primates type 12 17beta-hydroxysteroid dehydrogenase.
Blanchard PG; Luu-The V
J Endocrinol; 2007 Aug; 194(2):449-55. PubMed ID: 17641292
[TBL] [Abstract][Full Text] [Related]
53. Abnormal expression of 17beta-hydroxysteroid dehydrogenases in breast cancer predicts late recurrence.
Gunnarsson C; Olsson BM; Stål O;
Cancer Res; 2001 Dec; 61(23):8448-51. PubMed ID: 11731426
[TBL] [Abstract][Full Text] [Related]
54. Substrate inhibition of 17β-HSD1 in living cells and regulation of 17β-HSD7 by 17β-HSD1 knockdown.
Han H; Thériault JF; Chen G; Lin SX
J Steroid Biochem Mol Biol; 2017 Sep; 172():36-45. PubMed ID: 28554725
[TBL] [Abstract][Full Text] [Related]
55. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationships.
Bydal P; Auger S; Poirier D
Steroids; 2004 May; 69(5):325-42. PubMed ID: 15219411
[TBL] [Abstract][Full Text] [Related]
56. Steroid sulfatase inhibition success and limitation in breast cancer clinical assays: An underlying mechanism.
Sang X; Han H; Poirier D; Lin SX
J Steroid Biochem Mol Biol; 2018 Oct; 183():80-93. PubMed ID: 29803725
[TBL] [Abstract][Full Text] [Related]
57. Pharmacophore modelling of 17beta-HSD1 enzyme based on active inhibitors and enzyme structure.
Karkola S; Alho-Richmond S; Wahala K
Mol Cell Endocrinol; 2009 Mar; 301(1-2):225-8. PubMed ID: 18822344
[TBL] [Abstract][Full Text] [Related]
58. Possible role of the aromatase-independent steroid metabolism pathways in hormone responsive primary breast cancers.
Hanamura T; Niwa T; Gohno T; Kurosumi M; Takei H; Yamaguchi Y; Ito K; Hayashi S
Breast Cancer Res Treat; 2014 Jan; 143(1):69-80. PubMed ID: 24292869
[TBL] [Abstract][Full Text] [Related]
59. In vitro interactions between mammary fibroblasts (Hs 578Bst) and cancer epithelial cells (MCF-7) modulate aromatase, steroid sulfatase and 17β-hydroxysteroid dehydrogenases.
Wang X; Sang X; Diorio C; Lin SX; Doillon CJ
Mol Cell Endocrinol; 2015 Sep; 412():339-48. PubMed ID: 26044867
[TBL] [Abstract][Full Text] [Related]
60. Focused libraries of 16-substituted estrone derivatives and modified e-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.
Vicker N; Lawrence HR; Allan GM; Bubert C; Smith A; Tutill HJ; Purohit A; Day JM; Mahon MF; Reed MJ; Potter BV
ChemMedChem; 2006 Apr; 1(4):464-81. PubMed ID: 16892382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
